| 2026-02-17 |
详情>>
业绩披露：
2026年一季报每股收益-0.04美元,归母净利润-32.46万美元,同比去年增长67.06%
|
| 2026-02-17 |
财报披露：
美东时间 2026-02-17 盘后发布财报
|
| 2026-02-12 |
股东大会：
将于2026-03-30召开股东大会
会议内容 ▼▲
- 1.The election of seven directors;
2.The ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2026;
3.To approve an amendment to our articles of incorporation, as amended, as set forth in Appendix A attached to this proxy statement, at the discretion of the board of directors (the “Board”), to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-ten (1:10), at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board (the “Reverse Split Proposal”);
4.To approve, in accordance with NYSE American Company Guide Section 713, the issuance of shares of common stock upon the conversion of Series B Convertible Preferred Stock (the “Series B”) and accrued or potential dividend shares pursuant to those certain securities purchase agreements dated September 29, 2025 (“Series B Purchase Agreements”) with four institutional investors (the “Series B Investors”), without giving effect to the exchange cap in the Series B Purchase Agreements, which may result in the issuance of more than 20% of the Company’s outstanding common stock immediately prior to such issuance, potentially resulting in significant dilution to existing shareholders (the “Series B 20% Issuance Proposal”);
5.To approve, in accordance with NYSE American Company Guide Section 713, the issuance of shares of common stock upon the conversion of Series C Convertible Preferred Stock (the “Series C”) and accrued or potential dividend shares pursuant to those certain securities purchase agreements dated December 18, 2025 (“Series C Purchase Agreements”) with two institutional investors (the “Series C Investors”), without giving effect to the exchange cap in the Series C Purchase Agreements, which may result in the issuance of more than 20% of the Company’s outstanding common stock immediately prior to such issuance, potentially resulting in significant dilution to existing shareholders (the “Series C 20% Issuance Proposal”);
6.To approve, in accordance with NYSE American Company Guide Section 713, the issuance of shares of the Company’s common stock pursuant to that certain securities purchase agreement dated December 15, 2025 (the “ELOC Agreement”) with C/M Capital Master Fund, LP, establishing an equity line of credit under which the Company may sell shares of common stock to C/M Capital Master Fund, LP from time to time in its sole discretion, without giving effect to the exchange cap in the ELOC Agreement, which may result in the issuance of more than 20% of the Company’s outstanding common stock immediately prior to such issuance (the “ELOC 20% Issuance Proposal”);
7.To approve the 2025 Equity Compensation Plan (the “2025 Plan”);
8.To consider and vote upon a proposal to adjourn the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Annual Meeting, there are not sufficient votes to approve any proposal (the “Adjournment Proposal”);
9.Any other business as may properly come before the meeting.
|
| 2026-01-20 |
详情>>
股本变动：
变动后总股本1049.56万股
|
| 2025-12-20 |
复牌提示：
2025-12-19 14:05:06 停牌，复牌日期 2025-12-19 15:20:00
|
| 2025-12-19 |
详情>>
业绩披露：
2025年年报每股收益-1.09美元,归母净利润-437.54万美元,同比去年增长43.21%
|
| 2025-11-28 |
详情>>
内部人交易：
Kennedy Thomas Ronan股份增加445000.00股
|
| 2025-08-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.56美元,归母净利润-369.54万美元,同比去年增长43.57%
|
| 2025-05-15 |
详情>>
业绩披露：
2025年中报每股收益-3.67美元,归母净利润-246.67万美元,同比去年增长58.94%
|
| 2025-04-29 |
详情>>
拆分方案：
每8.0000合并分成1.0000股
|
| 2025-02-25 |
股东大会：
将于2025-04-10召开股东大会
会议内容 ▼▲
- 1.The election of seven directors;
2.The ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.The approval and adoption of an amendment to the Company’s Certificate of Designation of Rights and Preferences of the 8% Series A Cumulative Convertible Preferred Stock, as set forth in Appendix A to the attached Proxy Statement, to provide that each share of Series A Preferred Stock will be automatically converted into thirteen shares of common stock (the “Series A Preferred Proposal”) upon the effective time of the amendment;
4.To approve an amendment to our articles of incorporation, as amended, as set forth in Appendix B to the attached Proxy Statement, at the discretion of the board of directors, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-ten (1:10), at any time prior to the one-year anniversary date of the annual meeting, with the exact ratio to be determined by the board (the “Reverse Split Proposal”);
5.To consider and vote upon a proposal to adjourn the annual meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the annual meeting, there are not sufficient votes to approve any proposal (the “Adjournment Proposal”);
6.Any other business as may properly come before the meeting.
|
| 2025-02-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.22美元,归母净利润-98.54万美元,同比去年增长50.66%
|
| 2024-12-18 |
详情>>
业绩披露：
2024年年报每股收益-1.79美元,归母净利润-770.41万美元,同比去年增长71.40%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.84美元,归母净利润-654.88万美元,同比去年增长34.93%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年中报每股收益-2.03美元,归母净利润-600.81万美元,同比去年增长17.63%
|
| 2024-02-14 |
股东大会：
将于2024-03-29召开股东大会
会议内容 ▼▲
- 1.The election of four directors;
2.The ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.A non-binding advisory vote on the frequency of an advisory vote on executive compensation;
4.A non-binding advisory vote on executive compensation;
5.The approval and adoption of an amendment to the Company’s Certificate of Designation of Rights and Preferences of the 8% Series A Cumulative Convertible Preferred Stock, as set forth in Appendix A to the attached Proxy Statement, to provide that each share of Series A Preferred Stock will be automatically converted into six shares of common stock (the “Series A Preferred Proposal”) upon the effective time of the amendment;
|
| 2024-02-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.67美元,归母净利润-199.7万美元,同比去年增长59.71%
|
| 2023-12-22 |
详情>>
业绩披露：
2023年年报每股收益-13.32美元,归母净利润-2694.02万美元,同比去年增长63.64%
|
| 2023-08-11 |
股东大会：
将于2023-09-22召开股东大会
会议内容 ▼▲
- 1.The approval and adoption of an amendment to the Company’s Certificate of Designation for the Series A Preferred Stock to provide that each share of Series A Preferred Stock will be automatically converted into three shares of common stock;
2.The approval of one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting.
|
| 2023-04-25 |
详情>>
拆分方案：
每45.0000合并分成1.0000股
|
| 2023-01-04 |
股东大会：
将于2023-02-16召开股东大会
会议内容 ▼▲
- 1.The election of four directors;
2.The ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.To approve an amendment to our articles of incorporation, as amended, at the discretion of the board of directors, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-twenty (1:20) to one-for-fifty (1:50), at any time prior to the one-year anniversary date of the annual meeting, with the exact ratio to be determined by the board;
4.Any other business as my properly come before the meeting.
|
| 2022-01-27 |
股东大会：
将于2022-03-11召开股东大会
会议内容 ▼▲
- 1.the election of six directors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.any other business as my properly come before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-25 |
股东大会：
将于2021-03-12召开股东大会
会议内容 ▼▲
- 1.the election of seven directors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.the approval of the 2021 Equity Compensation Plan;
4.non-binding advisory vote on executive compensation;
5.any other business as my properly come before the meeting.
|
| 2020-03-11 |
股东大会：
将于2020-04-23召开股东大会
会议内容 ▼▲
- 1.The election of six directors;
2.The ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.Any other business as my properly come before the meeting.
|
| 2019-03-21 |
股东大会：
将于2019-04-19召开股东大会
会议内容 ▼▲
- 1.the election of nine directors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.to approve the possible issuance (the “Stock Issuances”) up to an aggregate of 30,500,000 shares of our common stock pursuant to rights granted as consideration for the mergers which closed on December 20, 2018 (the “Transaction”) pursuant to the terms of the Agreement and Plan and Merger dated December 3, 2018 (the “Merger Agreement”) by and among Level Brands, Inc., its wholly-owned subsidiaries AcqCo LLC and cbdMD LLC, and Cure Based Development, LLC (“Cure Based Development”);
4.to approve an amendment to our articles of incorporation to change the name of our company to “cbdMD, Inc.” (the “Name Change”);
5.to approve an amendment to the 2015 Equity Compensation Plan to increase the number of shares available for issuance under the plan (the “2015 Plan Amendment”);
6.any other business as my properly come before the meeting.
|
| 2018-01-29 |
股东大会：
将于2018-03-22召开股东大会
会议内容 ▼▲
- 1.the election of seven directors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm;
3.a non-binding advisory vote on the frequency of an advisory vote on executive compensation;
4.a non-binding advisory vote on executive compensation;
5.any other business as my properly come before the meeting.
|